Results 101 to 110 of about 4,026 (142)

Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea

Gut and Liver
Background/Aims : Tenofovir alafenamide (TAF) has emerged as a safe and effective alternative to entecavir (ETV) in the management of chronic hepatitis B (CHB).
Hyunjae Shin, Moon Haeng Hur, Yang Hyun Baek, Chun Kyon Lee, Yong Kyun Cho, June Sung Lee, Jae Yoon Jeong, Yong Jin Jung, Ja Kyung Kim, Moon Young Kim, Yeon Seok Seo, Woo Jin Chung, Moon Soo Koh, Jeong-Han Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim   +19 more
doaj   +1 more source

Advanced virological response to Entecavir therapy in CHB patients with and without hepatic steatosis.

, 2012
Advanced virological response to Entecavir therapy in CHB patients with and without hepatic steatosis.
Yi-peng Chen (174306), Yi-da Yang (174315), Chuan-qing Xu (174334), Xi Jin (174296), Lin Zheng (109927), You-ming Li (174325)   +5 more
core   +1 more source

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance

, 2015
Guiliang Wang,1,2 Yan Liu,2 Ping Qiu,1 Shu-Feng Zhou,3,4 Linfang Xu,1 Ping Wen,1 Jianbo Wen,1 Xianzhong Xiao5 1Department of Digestive Internal Medicine, Gannan Medical University Pingxiang Hospital, Pingxiang, People’s Republic of China ...
Xu L, Liu Y, Wen J, Zhou SF, Xiao X, Wen P, Wang G, Qiu P   +7 more
core  

Comparative Efficacy and Renal Safety of Entecavir and Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B: A Retrospective Cohort Study From Vietnam

Pharmacology Research & Perspectives
Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first‐line antiviral agents for chronic hepatitis B (CHB), yet comparative real‐world data in Southeast Asian populations remain limited.
Thong Duy Vo, Han Ngoc Gia Nguyen, Sang The Phan   +2 more
doaj   +1 more source

Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial

, 2018
Eun Ju Cho,1 Su Jong Yu,1 So Young Kwon,2 Ji-Hoon Kim,3 Do Young Kim,4 Won Kim,5 June Sung Lee,6 Jin Woo Lee,7 Youn Jae Lee,8 Hee Bok Chae,9 Jung-Hwan Yoon1 1Department of Internal Medicine, Liver Research Institute, Seoul National University College of
Yu SJ, Lee JS, Kim DY, Kim W, Kwon SY, Cho EJ, Kim JH, Yoon JH, Lee YJ, Lee JW, Chae HB   +10 more
core  

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? [PDF]

Clinical and Molecular Hepatology, 2020
Byoung Kuk Jang
doaj   +1 more source

Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels

The long-term kinetics of quantitative HBsAg levels in HBV-infected patients treated with entecavir or tenofovir, as well as the role of quantitative HBsAg in predicting functional cure (HBsAg loss) and low HBsAg levels (p p < 0.05).
Jung Hyun Kwon, Jeong Won Jang, Soon Woo Nam, Soon Kyu Lee   +3 more
core   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Entecavir

Nature Reviews Drug Discovery, 2005
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Peter Kirkpatrick
exaly   +3 more sources

Entecavir

Reactions Weekly, 2011
The oral deoxyguanosine nucleoside analogue entecavir (Baraclude®) has potent activity against hepatitis B virus (HBV) and a high genetic barrier to resistance.
Gillian M. Keating, Keating, Gillian M
openaire   +2 more sources

Entecavir

Reactions Weekly, 2022
  +4 more sources